(Length of Discussion: 15 min)

Lawrence I Karsh discusses SpaceOAR Hydrogel and it's use as a prostate-rectum spacer for treating prostate cancer with radiation therapy. 

He presents a study he took part in which aimed to evaluate the safety of the prostate-rectum spacer application technique as well as the following: the implant quality and resulting rectal dose reduction, acute and long term rectal, urinary and sexual toxicities and lastly, patient reported outcomes.  He highlights the spacer application was well tolerated with a 99% technical success rate.

Prostate-rectum hydrogel spacer application is a relatively safe technical procedure which is well tolerated and has a high technical success rate. Spacer application significantly reduces rectal radiation dose, and results in long-term reductions in rectal toxicity as well as improvements in bowel, urinary and sexual quality of life.


Biography: 
Lawrence I. Karsh, MD, FACS - Attending Urologist, Director of Research and Co-Director ATC at the Urology Center of Colorado 

Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.

Augmenix® Announces Medicare Reimbursement Rates, Effective January 2018

Hydrogel injection reduces rectal toxicity after radiotherapy for localized prostate cancer.

Watch: Hydrogel Spacer Prospective Pivotal Trial - Neil Mariados